# BRAF mutation in thyroid cancer

Source: https://onco.cc/key-papers/paper-braf-thyroid-endocr-relat-cancer-2005/  
OnCo record `paper-braf-thyroid-endocr-relat-cancer-2005` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Review on BRAF in Thyroid cancer, in Endocrine-related cancer (2005), one of the most cited Europe PMC records with BRAF in its title.

## Summary

Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon which novel approaches to the management of thyroid cancer can be developed. A recent important genetic finding in thyroid cancer is the oncogenic T1799A transversion mutation of BRAF (the gene for the B-type Raf kinase, BRAF). Since the initial report of this mutation in thyroid cancer 2 years ago, rapid advancements have been made. BRAF mutation is the most common genetic alteration in thyroid cancer, occurring in about 45% of sporadic papillary thyroid cancers (PTCs), particularly in the relatively aggressive subtypes, such as the tall-cell PTC. This mutation is mutually exclusive with other common genetic alterations, supporting its independent oncogenic role, as demonstrated by transgenic mouse studies that showed BRAF mutation-initiated development of PTC and its transition to anaplastic thyroid cancer. BRAF mutation is mutually exclusive with RET/PTC rearrangement, and also displays a reciprocal age association with this common genetic alteration in thyroid cancer. The T1799A BRAF mutation occurs exclusively in PTC and PTC-derived anaplastic thyroid cancer and is a specific diagnostic marker for this cancer when identified in cytological and histological specimens. This mutation is associated with a poorer clinicopathological outcome and is a novel independent molecular prognostic marker in the risk evaluation of thyroid cancer. Moreover, preclinical and clinical evaluations of the therapeutic value of novel specific mitogen-activated protein kinase pathway inhibitors in thyroid cancer are anticipated. This newly discovered BRAF mutation may prove to have an important impact on thyroid cancer in the clinic.

Indexed on Europe PMC as PubMed record 15947100 (DOI 10.1677/erc.1.0978). Its title names BRAF and its text names Thyroid cancer; PubMed types it as a review (Research Support, Non-U.S. Gov't, Review). It was matched automatically to the idea "BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer" and no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Endocrine-related cancer
- Year: 2005
- DOI: 10.1677/erc.1.0978
- Authors: Xing M
- What it means: One of the most cited reviews Europe PMC returns for BRAF in Thyroid cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Caveats: Matched by BRAF in the title and Thyroid cancer in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; A review summarises other studies; the primary reports it cites are the evidence.

## Sources

- Endocr Relat Cancer 2005: https://doi.org/10.1677/erc.1.0978
- PubMed: https://pubmed.ncbi.nlm.nih.gov/15947100/
- Europe PMC: https://europepmc.org/article/MED/15947100

## Connected records

- journals: [Endocrine-related cancer](https://onco.cc/journals/endocrine-related-cancer/)
- ideas: [BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer](https://onco.cc/ideas/idea-atc-triplet-io/)

---
JSON: https://onco.cc/api/v1/entities/paper-braf-thyroid-endocr-relat-cancer-2005.json